Trial Profile
Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Gemcitabine (Primary) ; Zoledronic acid (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms SUCCESS-A
- 05 Jun 2018 Results assessing the prognostic impact of circulating tumour cells to predict late recurrences during long-term follow-up (n=206) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Results assessing circulating tumour cell counts (n=311) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 18 May 2015 New trial record